Close Menu


The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.

In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.

CEO Troy Wilson unveiled the first data on tipifarnib demonstrating that biomarkers in the CXCL12 pathway identify which peripheral T-cell lymphoma patients respond best.